Logo

Frank Witney

Jun 22, 2016

Gyros Protein Technologies has appointed Frank Witney as a chairman of the board. Witney succeeds David Patterson, who remains at the company as a director. Most recently, Witney served as president and CEO of Affymetrix, which was acquired by Thermo Fisher Scientific in March 2016. He also served as president and CEO of Dionex, which was also acquired by Thermo Fisher Scientific, and has held executive roles at various companies — he was president and CEO of Panomics, which was acquired by Affymetrix, and chief operating officer of Packard Biosciences, which was acquired by PerkinElmer.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.